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ABSTRACT
Asplenic or hyposplenic (AH) individuals are particularly vulnerable to invasive infections caused by
encapsulated bacteria. Such infections have often a sudden onset and a fulminant course. Infectious diseases
(IDs) incidence in AH subjects can be reduced by preventive measures such as vaccination. The aim of our work
is to provide updated recommendations on prevention of infectious diseases in AH adult patients, and to
supply a useful and practical tool to healthcare workers for the management of these subjects, in hospital
setting and in outpatients consultation. A systematic literature review on evidence based measures for the
prevention of IDs in adult AH patients was performed in 2015. Updated recommendations on available vaccines
were consequently provided. Vaccinations against S. pneumoniae, N. meningitidis, H. influenzae type b and
influenza virus are strongly recommended and should be administered at least 2 weeks before surgery in
elective cases or at least 2 weeks after the surgical intervention in emergency cases. In subjects without
evidence of immunity, 2 doses of live attenuated vaccines against measles-mumps-rubella and varicella should
be administered 4–8 weeks apart from each other; a booster dose of tetanus, diphtheria and pertussis vaccine
should be administered also to subjects fully vaccinated, and a 3-dose primary vaccination series is
recommended in AH subjects with unknown or incomplete vaccination series (as in healthy people). Evidence








The spleen is crucial in regulating immune homeostasis through
its ability to link innate and adaptive immunity and in protecting
against infections. The term “asplenia” refers to the absence of
the spleen, a condition that is rarely congenital and mostly post-
surgical (due to splenic rupture from trauma or for haematologi-
cal, immunological, or oncological reasons). The impairment of
splenic function is defined as hyposplenism, an acquired disor-
der caused by several diseases (haematological and immunologi-
cal disorders, malaria, splenic vein thrombosis, infiltrative
diseases such as sarcoidosis, amyloidosis, tumors or cysts).
Asplenia and hyposplenia are important risk factors for invasive
infections in particular with encapsulated bacteria as Streptococ-
cus pneumoniae (responsible for more than 50% of infections),
Haemophilus influenzae type b, Neisseria meningitidis. The
term “overwhelming post-splenectomy infection” (OPSI) refers
to a rapid fatal syndrome occurring in individuals following
removal of the spleen, but is largely interchangeable with
“asplenic sepsis.” OPSI can progress from a mild flu-like illness
to fulminant sepsis in a short time period and has high mortality
rate (up to 50% despite maximal treatment).1 Estimated inci-
dence of OPSI is around 0.23–0.42% per year, with a lifetime
risk of 5%.2 Although the risk of OPSI has been reported poten-
tially life-long,3,4 is commonly accepted that the highest fre-
quency of life-threatening infectious episodes is observed during
the first 2 y (near 30% of episodes occur within the first year after
splenectomy and 50% within the first 2 years).5-7
The infectious risk is higher in subjects affected by haemato-
logical diseases as sickle cell anaemia and thalassemia major or
lymphoproliferative disorders (e.g. Hodgkin’s disease, non-
Hodgkin’s lymphomas etc.).8,9
Furthermore, age at time of splenectomy seems to play an
important role in determining risk of infection: incidence of
OPSI is higher in patients younger than 16 y (particularly youn-
ger than 5 y).2,9 The mainstays of infectious diseases prevention
in asplenic and hyposplenic (AH) subjects include: 1) patient
and family education, 2) vaccinations, 3) prophylactic antimi-
crobial therapy in selected people, 4) early empirical antimicro-
bial therapy for febrile episodes, 5) early management of animal
bites, 6) malaria prophylaxis for travelers in endemic countries.
The past decade has seen increased efforts to highlight the risks
of infection in asplenic patients, to improve general awareness,
and to give advice on appropriate precautions to prevent OPSI.
Despite all such efforts, reports of OPSI cases continue to occur.1
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The aim of our work is to provide updated recommenda-
tions on prevention of infectious diseases in AH adult patients,
and to supply a useful and practical tool to healthcare workers
for the management of these subjects. Therefore, in 2015, we
performed a literature review in Medline using the keywords
“asplenic” or “hyposlenic” combined with “prevention” or
“vaccination.” Overall 95 papers were selected and reviewed. In
particular, we focused on available vaccines, the schedule and
timing for doses administration, and antibiotic prophylaxis.
These recommendations are also based on the consensus and
opinion of the authors, who are experts in the fields of immu-
nology, infectious diseases and public health. Results of the lit-
erature review are reported in the following sections and a
summary of recommendations, is shown in Table 1.
Pneumococcal vaccination
There are 2 types of pneumococcal vaccine currently available
for adults in Italy: - Pneumococcal 13-valent conjugate vaccine
(PCV13), contains polysaccharides from different capsular types
of S. pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,
23F). These polysaccharides are conjugated to the CRM197 car-
rier protein and adsorbed on aluminum phosphate. PCV13 is
authorized for all ages; it is approved for the prevention of pneu-
mococcal pneumonia, pneumococcal invasive disease and, in
subjects under 18 years, also for otitis.
- Pneumococcal polysaccharide vaccine (PPSV23), contains
purified capsular polysaccharide from 23 capsular types of S.
pneumoniae (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F). This vaccine is
authorized for people aged >2 y. PPSV23 is approved for the
prevention of pneumoccocal invasive diseases.
Conjugate vaccines elicit a T-cell dependent immune
response and is more immunogenic than vaccines with polysac-
charides alone;10 it induces long-term protection, immunologic
memory and has boosting effect with a better immunologic
response when used for priming.11,12 Furthermore, PCV13
seems to be immunogenic if used as a booster dose in patients
with previous PPSV23 vaccination.13 A recent study suggests
that conjugated vaccine may be the most suitable choice to gen-
erate IgG-mediated protection in asplenic patients.14 Polysac-
charide vaccine elicits T cell independent immune responses, it
is a poor inducer of immunologic memory and it is associated
with immunological hyporesponsiveness to subsequent vacci-
nations. The immune response is poor or inconsistent in chil-
dren aged < 2 y and in patients with immune deficiency.
Table 1. Indications, doses, timing of the main vaccinations and booster doses in asplenic subjects or candidates for splenectomy.
Vaccine Indications and doses Timing of vaccination Booster doses
Pneumococcal @ Na€ıve subjects: PCV13 (1 dose) followed by PPSV23 (1
dose) at least 8 weeks later.
In case of splenectomy: PPSV23: 1 dose 5 years
after PPSV23
@ In patients who have previously received PPSV23,
administer PCV13  1 year later.
-At least two weeks
before elective
surgery 4,5
@ In patients who have previously received PCV13, repeat
1 dose of PCV13 followed by PPSV23  8 weeks later.
-After two weeks post-
operatively in
emergency cases
Meningococcal @ Na€ıve subjects: 2 doses of Men ACWY conjugate vaccine
given 8–12 weeks apart from each other.1
In case of functional
asplenia: as soon as
possible
Men ACWY: 1 dose
every 5 years
@ In patients previously vaccinated with a single dose of
Men ACWY or Men C, repeat the entire cycle (2 doses
8–12 weeks apart from each other)1
MenB: not
recommended
@ Men B vaccine: 2 doses administered at least 2 months
apart from each other.
Haemophilus influenzae type b @ Na€ıve subjects: 1 dose of conjugate Hib vaccine1 Not recommended
@ In subject previously vaccinated, ripeat 1 dose of
conjugate Hib vaccine1
Influenza @ Administer 1 dose of flu vaccine Yearly (October)
Measles Mumps Rubella 2 doses of MMR administered 4–8 weeks (preferably three
months) apart from each other in subjects without
evidence of immunity2,3
Not recommended
Varicella 2 doses of V-containing vaccine administered 4–8 weeks
(preferably three months) apart from each other in
subjects without evidence of immunity2,3
Not recommended
Tetanus diphteria pertussis @ Na€ıve subjects or subjects who are not fully vaccinated
(3 doses): repeat the entire cycle
1 Dose every 10 years
@ In subjects previously vaccinated with a primary cycle:
1 booster dose
1Administration of vaccines outside the age groups indicated in the Summary of Product Characteristics (SPC) must be motivated, shared with the patient and recorded.
2The subjects are defined as “previously vaccinated” on the basis of medical history data (previous infection) or vaccination certificate. In dubious cases it is necessary to
carry out a determination of serum antibody titer.
3In patients with concomitant immunosuppressive diseases or treatment with immunosuppressive drugs it is necessary to evaluate case by case, the decision to adminis-
trate live viral attenuated vaccines. Under such conditions, specialists in the field should be consulted.
In general:
-Subjects with lymphocyte deficit should not receive live viral attenuated vaccines.
-Subjects with neutropenia should not receive live attenuated bacterial vaccines.
4Preferably 4–6 weeks prior to splenectomy.
5In case of chemo- or radio therapeutic treatment vaccinations should be administered at least 2 weeks before or 3 months after the treatment.
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A recent study shows that PPSV23 may deplete the preexisting
pool of peripheral memory B cell because polysaccharide anti-
gens drive memory B cells into terminal differentiation without
reintegrating the memory B-cell pool.15 Failures of PPSV23
vaccine have been reported. In asplenic patients it can be due
to underlying condition (i.e. hematological malignancies) or to
immunosuppression. Some authors hypothesize that a poor
antibody response may be genetically regulated.16-18
We recommend the following pneumococcal vaccine strat-
egy for asplenic adults. In na€ıve patients administer PCV13 (1
dose) followed by PPSV23 at least after 8 weeks to extend sero-
type coverage. Some experts suggest to repeat 1 dose of PCV13
1 y after PPSV23, to restore the memory B cell pool.14,15,19 In
patients who have previously received PPSV23, administer
PCV13 at least 1 y after the PPSV23.20,21 Asplenic patients who
previously received one or more doses of PPSV23 had a dose
(negative) and time (positive) related response.19 Conjugate
vaccine seems to be able to restore the memory B-cell pool
decreased by a previous PPSV23 dose,15 but the timing and
dosing required have not been clearly determined yet.19,20 In
patients who have previously received PCV13, administer
PPSV23 at least 8 weeks after PCV13. Repeat one dose of
PCV13 if the previous dose was given more than 5 y before,
then administer PPSV23 at least after 8 weeks. PCV13 should
be administered first. Administer a second dose of PPSV23 at
least 5 y after the first dose of PPSV23.22-24,25
Ideally patients should receive pneumococcal vaccine from 4
to 6 weeks before elective splenectomy or initiation of chemo-
therapy or radiotherapy.
If it is not possible, vaccination should be administered at
least 2 weeks pre-operatively in elective cases or at least 2 weeks
post-operatively in emergency cases.17,22,24
In case of chemotherapy or radiotherapy administer vaccines at
least 2 weeks before treatment or 3 months after. Doses adminis-
tered during chemotherapy cannot be considered effectives.23,26,27
Vaccination is administered by intramuscular injection. Under
specific conditions, it can be given also as a subcutaneous injection.
The preferred injection site in adults is the deltoidmuscle.
PPSV23 safety was assessed both for immediate adverse reac-
tion and for long-term ones. PCV13 seems to have a similar profile
risk, even if data on long-term adverse reaction in adults are not
available. Common reactions reported include fever, irritability,
injection site erythema, induration/swelling or pain/tenderness,
decreased appetite, sleep disturbances. Infrequent reactions include
rash, anaphylactic reaction, shock and angioedema. Lymphade-
nopathy at the injection site is very rare.23
Contraindications for both PCV13 and PPSV23 vaccine are
a confirmed anaphylactic reaction to a previous dose of the vac-
cine or a confirmed anaphylactic reaction to any component of
the vaccine.
Precautions to be taken are pregnancy, acute severe or mod-
erate illness with or without fever, allergic reaction to the latex
(if in the syringe) and only for PPSV23 previous doses of the
same vaccine.28,29
Meningococcal vaccination
Meningococcal vaccines commercially available are conjugated
vaccines (linked to a protein to make them more effective and
immunogenic) and inactivated (obtained from the bacterium
fragments). Vaccination is administered by intramuscular
injection. Conjugate formulation provides immunological
memory and protection of longer duration than polysaccharide
vaccines.30
In Italy the following types of meningococcal conjugate vac-
cines are available:
1) monovalent conjugate vaccines against serotype C
(MenC). They are used in children as young as 2 months
of age, adolescents and adults. They are available in for-
mulations: a conjugate vaccine with the carrier protein
CRM197 of Corynebacterium diphtheria and an oligo-
saccharide conjugate vaccine with the carrier protein
CRM197 Corynebacterium diphtheriae;
2) tetravalent conjugate vaccine (Men ACWY), which pro-
tects against meningococcal serotypes A, C, W135 and
Y; it is available in 2 formulations: conjugated to Coryne-
bacterium diphtheriae CRM197 protein that is used in
children (aged 2 y old), adolescents and adults and con-
jugated to the tetanus toxoid carrier protein that is used
in subjects from 12 months of age and older;
3) vaccine against meningococcal serogroup B, developed
with the “reverse vaccinology” technique, are based on
the study of the bacterial DNA. The vaccine is formed by
4 antigenic components of N. meningitidis group B
exposed on the surface of the bacterium: the recombi-
nant fusion protein NHBA (Neisseria Heparin Binding
Antigen), the recombinant protein NadA (Neisseria
adhesin A), the recombinant fusion protein fHbp (factor
H binding protein), the outer membrane vesicles (OMV)
of the bacterial strain NZ98 / 254 measured as the
amount of total protein containing Pora P1.4. It is used
in individuals from 2 months of age and older.31,32
The immunogenicity of conjugated meningococcal vaccines
is evaluated in terms of serum bactericidal activity (SBA) and
measured by geometric mean title (GMT).33 Despite the lower
levels of antibodies produced by AH patients following vaccina-
tion than those produced by healthy immunocompetent sub-
jects, 80% of them reaches SBA values equal to or exceeding
the threshold value of protection,33,34 particularly after the
administration of a second dose of vaccine.35-37
A quadrivalent conjugate meningococcal vaccine is the pre-
ferred choice for protection against meningococcal diseases of
subjects at risk, as AH adults patients.
Such patients should receive a primary series of Men ACWY
of 2 doses given 8–12 weeks apart. Based on the technical
details, the vaccine is indicated for subjects aged between 2 and
55 y old. Vaccination of older subjects must be motivated,
shared with the patient and recorded.33 Booster doses should
be given every 5 y to asplenic patients in order to maintain a
high level of protective circulating antibodies.30,33,38,39
In adults, is recommended the administration of 2 doses of vac-
cination against meningococcus B at least 2months apart; there are
no evidence at this time to recommend booster doses.24
All patients who must undergo elective splenectomy should
receive a dose of meningococcal conjugate vaccine at least
2 weeks before surgery to optimize the immune response;26,39 if
it is not possible to respect this timing, it is recommended to
carry out the vaccination at least 2 weeks after surgery.40-43
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For asplenic subjects requiring chemotherapy, vaccination
should be performed at least 2 weeks before starting treatment
or 3 months after the end of therapy; doses of vaccine adminis-
tered during chemotherapy cannot be considered effective.26
Meningococcal vaccines have been formulated for intramus-
cular administration in the deltoid region in adolescents and
adults.32 Meningococcal vaccines have a good safety profile.
Adverse reactions following vaccination are usually mild and
are mainly represented by erythema (19.7%), edema and pain
at the injection site (13.7%), fever (16.8%), headache (16.0%),
irritability, nausea, vomiting, rash, itching, illness, lymphade-
nopathy, hypotonia, paresthesia, fainting. There are few reports
of hypersensitivity reactions (including anaphylaxis, broncho-
spasm and angioedema) and seizures.30 Local and systemic
reactions are of the same magnitude after the administration of
the first dose or boosters.33
Contraindications to the administration of meningococcal
vaccines (including meningococcal C, Men ACWY and menin-
gococcal B) are represented by a severe allergic reaction (ana-
phylaxis) to a previous dose of meningococcal vaccines or to a
component of the vaccine (including tetanus toxoid or
diphtheria).
The presence of acute illness, severe or moderate, with or
without fever and / or severe allergic reaction to latex (for prod-
ucts that contain latex in the syringe) should be considered as
precautions for administration of anti-meningococcal
vaccines.29,30,32,33
Pregnancy and breastfeeding do not represent conditions to
postpone meningococcal vaccination in patients with asplenia;
in fact, clinical risks due to the asplenic condition are higher
than any eventual side effects resulting from vaccination.
Haemophilus influenzae vaccination
Currently, only protection against Haemophilus influenzae
type b (Hib) strains is available; vaccines against non type b or
non typeable strains do not exist. Hib vaccine consist of puri-
fied component of the bacterial capsule (polyribosyl ribitol
phosphate; PRP). Conjugation of the PRP polysaccharide with
protein carriers, that contain T-lymphocyte epitopes, confers
T-lymphocyte dependent characteristics to the vaccine; this
conjugation enhances the immunologic response to the PRP
antigen and results in immunologic memory. There are actually
3 types of conjugate vaccine, utilizing different carrier proteins
for the conjugation process, all of which are highly effective
and safe: inactivated tetanospasmin (also called tetanus toxoid),
mutant diphtheria protein, and meningococcal group B outer
membrane protein. Hib conjugate vaccines are highly immuno-
genic: more than 95% of subjects will develop protective anti-
body levels after a primary series. Furthermore, clinical efficacy
has been estimated at 95% to 100%.44,45
Hib vaccine is also immunogenic in patients with increased
risk for invasive disease, such as those who have had a splenec-
tomy: case series show a modest increase in antibody responses
after vaccination, but always above the protective level (0.15mg/
mL).42,45,46
It is well known that vaccine-induced anti-PRP antibody
levels decline over time below the putative protective threshold,
but it is not clear whether the apparent decline in protection in
these patients may be accompanied by an increase in suscepti-
bility to Hib disease.45,46
However, specific studies of efficacy have not been per-
formed in populations with increased risk of invasive disease.44
International guidelines recommend administration of a single
dose of any licensed Hib conjugate vaccine to unimmunized
adults who are asplenic or who are scheduled for an elective
splenectomy;26,47 taking into account the decline in antibody
levels over time, some experts suggest administering a dose
regardless of prior vaccination history.43,45,48 Considering the
low reactogenicity and the low cost of anti-Hib vaccine, and the
lack of access to the assessment of post-vaccination antibodies,
we suggest vaccination against Hib in asplenic and hyposplenic
subjects, regardless of the history of vaccinations in order to
increase antibody titers. Currently, there is no evidence to
recommend booster doses of Hib-vaccine.
Regarding the timing, vaccine should be administered at
least 2 weeks before splenectomy in elective cases (preferably
4–6 weeks before) or at least 2 weeks after surgery in emergency
case. 26,39,42,43,47
Hib-vaccine should ordinarily be administered as soon as
possible after recognition of non-surgical hyposplenism but
specific scheduling may be required in the context of recovery
from any immunosuppression. In adult patients, Hib vaccines
could be administered intramuscularly at the level of the del-
toid.47 Adverse reactions to Hib-vaccines are uncommon, usu-
ally mild (swelling, redness and pain at the punctio), and
generally resolve within 12–24 hours.44,49,50 Systemic reactions
such as fever, convulsions, irritability and cyanosis are uncom-
mon and occur at the same frequency of DTaP vaccination;
serious systemic reactions are rare (incidence rate of anaphy-
laxis from 0.65 to 3 per million vaccine doses adminis-
tered).44,49 Vaccination with a Hib-containing vaccine is
contraindicated in infants aged <6 weeks and among persons
known to have a confirmed anaphylactic reaction to a previous
dose of a Hib-containing vaccine, or to any components of the
vaccine.50
Minor illnesses without fever or systemic upset are not valid
reasons to postpone immunisation; if an individual is acutely
unwell, immunisation may be postponed until they have
recovered.50
Hib-containing vaccines may be given to pregnant women
when protection is required without delay; there is no evidence
of risk from vaccinating pregnant women or those who are
breast-feeding with inactivated viral or bacterial vaccines or
toxoids.50
Influenza vaccination
Influenza vaccines are annually prepared using virus strains in
line with the WHO recommendations, based on surveillance
data indicating which viruses are circulating and forecasts
about which viruses are the most likely to circulate during the
coming season. Flu vaccines for adults are available either as a
trivalent (containing 2 subtypes of influenza A and one B virus)
or quadrivalent (with an additional B virus) injection. The vac-
cines contain inactivated viruses and induce protection after
injection (typically intramuscular, though subcutaneous and
intradermal routes can also be protective) based on an immune
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response to the viral antigens. The influenza vaccination effort
protection from influenza syndrome and secondary bacterial
infection (particularly due to S.pneumoniae and S.aureus).39,51
In asplenic patients, influenza immunization is associated
with a 54% reduced risk of death compare with unimmunized
asplenic persons.52 Therefore international guidelines recom-
mend annual influenza vaccine for hyposplenic or asplenic
patients; the vaccine could be administered before or after sple-
nectomy, preferably in October to afford seasonal
protection.26,39,43,53,54
Redness, swelling, hardness at the injection site are the most
common local reactions following immunization (about 15%
after intramuscular vaccine, and 61% after intradermal vac-
cine); these symptoms may occur between 6 and 24 hours after
vaccination and have short duration (maximum 2 days).55 Sys-
temic symptoms include mild flu-like manifestations (approxi-
mately 42% of subjects) and have the same duration of local
symptoms. Anaphylactic reactions are rare.53,56
Vaccination with influenza vaccine is contraindicated in
persons known to have a confirmed anaphylactic reaction to a
previous dose of the vaccine, or to any components of the vac-
cine. In recent years, inactivated influenza vaccines that are
egg-free or have a very low ovalbumin content have become
available and studies show they may be used safely in individu-
als with egg allergy.
Minor illnesses without fever or systemic upset are not valid
reasons to postpone immunisation; if an individual is acutely
unwell, immunisation may be postponed until they have
recovered.53
A definite causal relationship between GuillainBarre syn-
drome (GBS) and influenza vaccines has not been established;
nevertheless it is to be considered as precaution an history of
Guillian-Barre syndrome within 6 weeks before.53
Tetanus, diphtheria, pertussis vaccination
Formulations of combined bivalent vaccines against diphtheria
and tetanus (bivalent) or trivalent vaccines, with the addition
of pertussis antigens or quadrivalent vaccine combinated to
IPV against poliovirus, or monovalent vaccines against tetanus
are currently available on the market. After the full vaccination
course and the following booster doses, efficacy of monovalent
and combined vaccines is almost 100% against tetanus. In
adults with unknown vaccination history 3 doses of dTap vac-
cine confer seroprotective titres against diphtheria and tetanus
comparable to titres obtained after vaccination with Td, more-
over the administration of multiple doses of dTap vaccine does
not cause an increase in reactogenicity, compared with admin-
istration of the Td vaccine.57-61
Indeed, booster doses with dTap induce an effective
response against pertussis, with an increase of antibodies titres
already after the first dose of vaccine, even in subjects never
immunized. Thus, the immunological response to booster
doses with pertussis-containing vaccines is effective even after
natural acquired immunity in subjects who experienced con-
tacts with Bordetella pertussis during their lifetime.62,63
In fact, protection induced by pertussis vaccination
decreases 4–12 y after the completion of a primary course and
4–20 y after natural infection, consequently incidence rates of
pertussis increase in adolescents and adults in absence of boos-
ters. The majority of pertussis cases could be avoided with the
introduction of early booster doses in adolescence and decen-
nial boosters in adulthood.64-66 Therefore, even in AH subjects,
previously vaccinated with a primary cycle, one booster dose
with dTap is recommended, while in na€ıve subjects or subjects
who are not fully vaccinated, the entire cycle should be
repeated. Moreover, for AH adult subjects decennial booster
doses with dTap vaccines are recommended, as for the general
population.68,69
In case of splenectomy, dTap vaccination should be admin-
istered at least 2 weeks before elective surgery, preferably
4–6 weeks, or after 2 weeks post-operatively in emergency
cases. In case of functional asplenia dTap vaccination is recom-
mended as soon as possible. In asplenic subjects requiring che-
motherapy and radiotherapy treatment, dTap vaccination
should be administered at least 2 weeks before or 3 months
after the treatment. Vaccine doses administered during the
treatment cannot be considered effective.26
The dTap vaccine is administered by intramuscular injection
at the level of the deltoid. Available vaccines for tetanus, diph-
theria and pertussis have a good safety profile; adverse effects
are usually mild and consist mainly in general reactions such as
fever, drowsiness and irritability and in local reactions such as
swelling (2%), erythema or edema (25–30%), pain at the injec-
tion site (50–85%). Many studies show an increased incidence
of local reactions with an increase in the number of doses
received, mainly due to the tetanus component. Guillain-Barre
syndrome and brachial neuritis associated with the tetanus vac-
cination, have been described, but are extremely rare (respec-
tively 0.4 cases per million doses and from 0.5 to 1 case per
100,000).58
Contraindications for dTap vaccine are a confirmed anaphy-
lactic reaction to a previous dose of the same vaccine or to any
vaccine component. Temporary contraindications are repre-
sented by acute illness, severe or moderate, with or without
fever and it is to be considered as precaution an history of Guil-
lian-Barre syndrome within 6 weeks after the administration of
a previous dose of vaccine.
The presence of severe allergic reaction to latex (for products
that contain latex in the syringe), a peripheral neuritis and
Arthus reaction after administration of a previous dose should
be considered as precautions for administration of dTap
vaccines.29,58
Measles, mumps, rubella, varicella vaccinations
Live attenuated vaccines for the prevention of measles, mumps,
rubella and varicella are available in Italy as combined trivalent
(MMR) or quadrivalent (MPRV) vaccines. Monovalent vac-
cines against varicella (V) are also available in Italy. In order to
reach a full protection 2 doses of vaccines are necessary in all
ages. The time interval between the first and the second dose
should be at least of 4–8 weeks; according to the epidemiologi-
cal context, in absence of an increased risk, a longer interval
(3 months) is desirable, as suggested by Canadian
recommendations.70
Protection afforded by a single dose of live attenuated mea-
sles containing vaccine is lifelong in most people. However, a
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small percentage (2–5%) of immunized subjects do not develop
immunity against measles after the first dose A second dose
assures protection against measles in more than 99% of sub-
jects. As far as mumps, the antibody levels after vaccination
decreased more than is the case of natural disease. The efficacy
of a single dose varies from 61% to 91%, for the mumps
component. The adoption of a 2 doses schedule in Finland and
Sweden determined a net reduction of the disease, while in
USA a 99% reduction of mumps cases was recently registered.
With regard to rubella, seroconversion in vaccinated subjects is
almost 100%; levels and duration (about 20 years) of antibody
titer are similar to natural disease.71-74
In all countries where varicella vaccination has been adopted
a great reduction of incidence and hospitalization rates was
observed.75 The vaccine has an efficacy of 80–90% in prevent-
ing infection, and 85–95% in preventing severe varicella cases.
76 However, breakthrough vericella cases were observed in
high-vaccinated populations and it is not clear if those cases are
due to a primary (inability to develop a protective immune
response after one dose of vaccine) or a secondary vaccine fail-
ure (waning immunity after a confirmed initial immune
response).77
For AH adults without evidence of immunity, vaccinations
against MMR and V are recommended in 2 doses, administered
4–8 weeks (preferably 3 months) apart from each other. Sub-
jects are defined as “previously vaccinated” on the basis of med-
ical history data (previous infection) or vaccination certificate.
In dubious cases it is necessary to carry out a determination of
serum antibody titer.22,25,26,78-81 Usually, live attenuated vac-
cines are contraindicated in severe immunocompromised
patients, while inactivated vaccines are strongly recommended
in subjects with primary or secondary immunodeficiency.82
In AH patients with concomitant immunosuppressive dis-
eases or treatment with immunosuppressive drugs, it is neces-
sary to evaluate case by case the decision to administrate live
viral attenuated vaccines. In general, subjects with lymphocyte
deficit should not receive live viral attenuated vaccines; while
subjects with neutropenia should not receive live attenuated
bacterial vaccines. Under such conditions, specialists in the
field should be consulted.
Regarding the timing, MMR or V vaccines should be admin-
istered at least 2 weeks before splenectomy in elective cases
(preferably 4–6 weeks before) or at least 2 weeks after surgery
in emergency case.26
Vaccinations against MMR and V are administered by sub-
cutaneous route in the deltoid region. Common reactions
reported for these vaccinations include fever episodes, occur-
ring 5–12 d after vaccination, injection site erythema or pain.
Some of the characteristic symptoms of the natural disease
such rash or swelling of the salivary glands and lymph nodes
can be developed. The vaccine viruses are not transmitted
from person to person like the corresponding natural virus:
accordingly, the recently vaccinated subjects, even if they
manifest the symptoms described above, are not contagious to
others.83-86 On the contrary, for varicella cases, when a vesicu-
lar erythema is developed after vaccination, the content liquid
can infect, by contact, a person who has never acquired the
disease or who has never been vaccinated. 87 Contraindica-
tions to MMR or V vaccines include severe immunodeficiency
(blood cancers and solid tumors, congenital immunodeficien-
cies as agammaglobulinemic, common variable immunodefi-
ciency or severe combined immunodeficiency; HIV with
severe immunosuppression) and confirmed anaphylactic reac-
tion to a previous dose of the same vaccine or to any vaccine
component.
Temporary contraindications are represented by pregnancy,
a severe or moderate illness, with or without fever, recent (at
least 11 months) immunoglobulin administration except for
post-exposure measles prophylaxis and long-term immunosup-
pressive therapy or transplantation of solid organ or staminal
cells. The presence of severe allergic reaction to latex (for prod-
ucts that contain latex in the syringe), acute to moderate illness,
history of arthritis after a first dose of MMR or rubella, history
of thrombocytopenia or thrombocytopenic purpura after a first
dose of MMR, especially if within 6 weeks and tuberculosis,
should be considered as precautions for administration of
MMR or V vaccines. Besides, for V vaccination precaution
should be taken in case of severe or recurrent infections and
use of aspirin or salicylates during the past 6 weeks.29,88
Prophylactic antimicrobial therapy
The introduction of vaccination in subjects with functional or
anatomic asplenia, has produced a significant reduction of
infections with encapsulated bacteria. However, no vaccine
reaches efficacy of 100%;89 this led to consider adding prophy-
lactic antibiotic therapy, typically oral penicillin twice a day, to
prevent streptococcal and meningococcal infections.
However, data are lacking to inform decision making in
many cases, because studies of the effectiveness of prophylactic
penicillin have been limited to children with sickle cell dis-
ease.90,91 Moreover these studies werecompleted before the uni-
versal use of pneumococcal conjugate vaccines92 and before an
increased prevalence of colonization and infection with penicil-
lin-resistant pneumococci.
Currently, based on these data and as a precaution, the inter-
national guidelines recommend antibiotic prophylaxis in children
younger than 5 y of age with asplenia for any reason.48,93
Conversely, there is no evidence available from randomized
control trials about efficacy of antibiotic prophylaxis in adults
and experts suggest very different approaches.39,43,48,94
As already mentioned, epidemiological data show an
increased risk of OPSI in subjects with haematological
diseases,8,9 in particular during the first years after splenectomy.
For these reasons we suggest prophylactic antibiotic therapy in
asplenic or hyposplenic adults affected by malignant haemato-
logical diseases (especially subjects who received irradiation of
the spleen or affected by GVH) for a period of 2 y.
Concerning the antibiotic therapy, it is necessary to mention
the management of febrile episodes: given the rapid evolution
of OPSI, patients should have a standby of broad-spectrum
antibiotics to start early empirical treatment in the event of any
sudden onset of unexplained fever, malaise, chills or other con-
stitutional symptoms, especially when medical review is not
readily accessible.
Lastly, there is an increased risk of OPSI in patients with
asplenia or hyposplenia who are bitten by dogs and other ani-
mals; the common causative organism is Capnocytophaga
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canimorsus. Such patients should be warned of this risk and
have adequate antibiotic cover following such bites, for exam-
ple, amoxycillin/clavulanic acid for 5 d.95
Conclusions
All asplenic and hyposplenic patients and their families should
be educated and given written information about the risk of
OPSI and strategies to minimize that threat, besides, their gen-
eral practitioners should be informed for the management of
infectious episodes. Vaccinations against S. pneumoniae, N.
meningitidis, H. influenzae type b and influenza virus are
strongly recommended and should be administered at least
2 weeks before surgery in elective cases or at least 2 weeks after
the surgical intervention in emergency cases. In subjects without
evidence of immunity, 2 doses of live attenuated vaccines against
measles-mumps-rubella and varicella should be administered
4–8 weeks apart from each other; a booster dose of dTap vaccine
should be administered also to subjects fully vaccinated, and a
3-dose primary vaccination series is recommended in AH sub-
jects with unknown or incomplete vaccination series (as in
healthy people). Early empirical antimicrobial therapy for febrile
episodes is indicated for these patients; they should have a
reserve or standby antibiotic supply with instructions to take in
the event of any sudden onset of unexplained fever, malaise,
chills or other constitutional symptoms. Prophylactic antimicro-
bial therapy is indicated in selected people. Currently, the use of
antibiotics for prevention of infections in asplenic-hyposplenic
adult patients is not evidence-based. An higher risk of OPSI is
documented in asplenic subjects with haematological malignan-
cies, especially in the first 2 y after splenectomy. Therefore, we
suggest therapy with oral penicillin in this category of patients
for a period of 2 y. Malaria prophylaxis for travelers in endemic
areas is recommended to avoid severe complications of the dia-
sease. Travelers should take the best precautions to prevent
infection by means of anti-malaric prophylaxis, mosquito repel-
lents and other barrier precautions. Advice from an infectious
disease physician or expert travel advisor is recommended
before departure. Evidence based prevention data to reduce the
risk of infection in AH individuals are accumulating and specific
hospital protocols should be available to all healthcare workers
in order to minimize the risk of infections potentially fatal in
those fragile patients.
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